Premature Ventricular Contractions (PVCs) Diagnosis and Treatment

Symptom Spectrum and Prevalence

Approximately 50% of all people have PVCs on extended monitoring, yet most remain completely unaware of them, with PVCs increasing in frequency with age, found in only 0.6% of healthy individuals under 20 years but 2.7% of those over 50 years on standard ECG, according to the American Heart Association 1
Asymptomatic PVCs generally do not require specific treatment, as stated by the European Society of Cardiology 2

In patients with diabetes and frequent PVCs, attempts to diagnose underlying structural heart disease should be considered, as recommended by the European Heart Society 3
PVCs during exercise testing are associated with higher mortality risk, and PVCs during recovery phase post-exercise are stronger predictors of death than those occurring only during exercise, according to the American College of Cardiology 4
Complex PVCs in endurance athletes may not be benign and warrant electrophysiological study to assess arrhythmogenic risk, as suggested by the American College of Cardiology 4

Beta blockers or non-dihydropyridine calcium channel blockers are first-line therapy to relieve palpitation symptoms, as recommended by the American College of Cardiology 4, 5
Antiarrhythmic medications are reasonable when beta blockers and calcium channel blockers are ineffective or not tolerated, according to the American College of Cardiology 5
Catheter ablation is useful for symptomatic outflow tract PVCs when medications fail, are not tolerated, or not preferred by the patient, as stated by the American College of Cardiology 5, 6
Pharmacologic treatment with beta blockers or amiodarone is reasonable to reduce arrhythmias and improve LV function in PVC-induced cardiomyopathy, as recommended by the American College of Cardiology 6

The American College of Cardiology recommends beta-blockers as first-line therapy for premature ventricular contractions (PVCs) in patients on vasopressors, starting with ultra-short-acting agents like esmolol 7
Amiodarone is a reasonable second-line therapy for patients who cannot tolerate beta-blockade or when beta-blockers are insufficient, particularly given its minimal negative inotropic effects compared to other antiarrhythmics 7

Patients with a PVC burden of >15% are at risk for PVC-induced cardiomyopathy and require more aggressive management, according to the American Heart Association, as published in Circulation 8, 7

The American College of Cardiology suggests considering catheter ablation if PVC burden remains >15% and is predominantly of single morphology, as this has 80% success rates and can normalize ventricular function within 6 months in patients with PVC-induced cardiomyopathy 8, 7
Continuing beta-blocker therapy after discharge in patients who had high PVC burden reduces recurrence risk and provides cardioprotective benefits, as recommended by the American College of Cardiology 7